Observatory of Prolymphocytic Leukemia T

Launched by FRENCH INNOVATIVE LEUKEMIA ORGANISATION · May 27, 2020

Keywords

ClinConnect Summary

This clinical trial is focused on studying prolymphocytic leukemia T (T-PLL), a rare and aggressive type of blood cancer that primarily affects older adults. The goal is to better understand this disease and improve treatment options for patients. Researchers are looking into how the disease behaves on a molecular level and how patients respond to different therapies, including a medication called alemtuzumab, which has shown some promise. They also hope to explore new treatments that could be easier for patients who cannot tolerate stronger chemotherapy.

To be eligible for this trial, participants need to be at least 18 years old and have been diagnosed with prolymphocytic T leukemia. Importantly, potential participants must be able to give their consent to join the study. If you or someone you know is facing this challenging diagnosis, this trial may offer a chance to contribute to important research that could lead to better management of T-PLL and improved survival outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Man or woman aged 18 or over
• • Patient with prolymphocytic T leukemia
• Exclusion Criteria:
• • Absence of signature of informed consent